The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PEPN1924, a phase 2 study of trastuzumab deruxtecan (DS-8201a, T-DXd) in adolescents and young adults with recurrent HER2+ osteosarcoma: A children’s oncology group pediatric early-phase clinical Trial Network study.
 
Damon R. Reed
Consulting or Advisory Role - Eisai; Pfizer; SpringWorks Therapeutics
 
Katherine A. Janeway
Honoraria - Foundation Medicine; Takeda
Consulting or Advisory Role - Bayer; Ipsen; Ipsen
Travel, Accommodations, Expenses - Bayer
 
Charles G. Minard
Other Relationship - CHEST Journal
 
David Hall
No Relationships to Disclose
 
Brian D. Crompton
Employment - Acceleron Pharma (I); Generate Biomedicines (I)
Stock and Other Ownership Interests - Acceleron Pharma (I)
Consulting or Advisory Role - Animal Cancer Foundation; AstraZeneca; PetDx
Research Funding - Gradalis
 
Alexander J. Lazar
No Relationships to Disclose
 
Wei-Lien Wang
No Relationships to Disclose
 
Stephan D. Voss
No Relationships to Disclose
 
Olga Militano
No Relationships to Disclose
 
Richard Greg Gorlick
Research Funding - Eisai (Inst)
 
Cheryl Ann Pickett-Gies
No Relationships to Disclose
 
Elizabeth Fox
No Relationships to Disclose
 
Brenda Weigel
No Relationships to Disclose